

Dr. Henning Gädeke

c/o Dr. Michael Makanga

Global Health EDCTP3 Joint Undertaking

56 – 60 Avenue de la Toison d’Or

1060 Brussels

Belgium

29th August 2025

Letter of endorsement

Dear Sir,

On behalf of the Centre for Research in Therapeutic Sciences - CREATES, Strathmore University, P.O. Box 59857 - 00200 Ole Sangale Road, Madaraka Estate, VAT number P051376916F and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

CREATES is a multidisciplinary consortium platform established in 2012 and based at Strathmore University, Kenya’s leading private university. Our mission aligns closely with the Global Health EDCTP3 JU’s objectives to accelerate the development of safe, effective, and accessible medical interventions for diseases of major public health concern in Africa. We focus on cutting-edge research in therapeutic sciences and genomics and the development of robust clinical trial platforms across the region. CREATES provides a framework for harnessing capacities to spur innovation and leverages on the facilities and resources provided by its location on Strathmore University’s Nairobi campus. The consortium has also contributed significantly in capacity building in the region through the training of students at MSc, PhD, clinical fellowships and postdoctoral level through mobility and exchange programmes.

CREATES pioneered Kenya’s first malaria challenge study and established a Controlled Human Malaria Infection (CHMI) platform. Its impact is reinforced by a strong scientific team working collaboratively with regional and global partners, and by robust fiduciary management that enables the effective stewardship of major institutional grants. These grants fund a wide portfolio of projects, including malaria vaccine development, clinical trials and research in sickle cell disease, HIV/AIDS, TB, preeclampsia, COVID 19, cardiovascular diseases, mental health, cancer, Leishmaniasis, nanomedicine, and drug discovery.

Our contribution to the Global Health EDCTP3 JU will primarily fall under In-Kind Contributions to Operational Activities (IKOP) over the course of the 5-year SINCEP-Africa (ID:101248792-2) project. CREATES will bring substantial added value to the program through its operational clinical trial sites in Nairobi and Western Kenya, its health and demographic surveillance platform in Kisumu County namely Kombewa and Nyando, its pharmacology laboratory in Nairobi and its proven expertise in ethical oversight, regulatory coordination, and pharmacovigilance systems. Our experience coordinating multi-stakeholder partnerships, receiving and managing funding from EDCTP, WHO, Gates Foundation, the Gates Research Institute, Wellcome Trust, Africa CDC, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Novo Nordisk, the National Research Funds of Kenya and South Africa, the National Cancer Institute of Kenya, DNDi, MMV, among others, positions us to directly support the

objectives of the Global Health EDCTP3 JU through innovation, designing and implementing research initiatives, capacity strengthening, regulatory strengthening, and community engagement.

Our proposed involvement is to lead Work Package 8 on Capacity strengthening and training and to co-lead Work Package 1 on Scientific leadership, partnership and networking. In addition, we will contribute to activities across all the work packages, including Scientific leadership, partnership and networking (WP1), Capacity assessment and infrastructure strengthening (WP2), Epidemiological preparedness, disease surveillance and population health (WP3), Ethics, regulatory, and pharmacovigilance (WP4), Clinical research and trial management (WP5), Social impact (WP6), Data science, artificial intelligence (AI) and analytics (WP7) and Capacity strengthening and training (WP8).

We estimate the total value of this contribution to be EUR 500,000 as in-kind for the 5 year grant/programme period.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

Florence Oloo

29th August 2025

Prof. Florence Oloo

Director

Centre for Research in Therapeutic Sciences-CREATES, Strathmore University